Emmanuel Bouillaud

KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.

David M. Brown, Andrés Emanuelli, Francesco Bandello et al. · Bern Open Repository and Information System (University of Bern) · 2022 · 145 citations · Full text

Medicine, Ophthalmology, Pharmacotherapy +17

KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema

Charles C. Wykoff, Justus G. Garweg, Carl D. Regillo et al. · American Journal of Ophthalmology · 2023 · 52 citations · Full text

Medicine, Ophthalmology, Pharmacotherapy +16

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study

Edward M. Wolin, Ke Hu, Gareth Hughes et al. · Cancer Chemotherapy and Pharmacology · 2013 · 43 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study

H. Dietrich, Ke Hu, Matthieu Ruffin et al. · European Journal of Endocrinology · 2012 · 35 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Pasireotide (SOM230), a Novel Multireceptor‐Targeted Somatostatin Analogue, Is Well Tolerated When Administered as a Continuous 7‐Day Subcutaneous Infusion in Healthy Male Volunteers

Stephan Petersenn, Nicole Unger, Ke Hu et al. · The Journal of Clinical Pharmacology · 2011 · 32 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +13